Advertisement

Topics

LYNPARZA® (olaparib) Receives Additional FDA Approval in the US for Ovarian Cancer

16:22 EDT 17 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
LYNPARZA’s new tablet formulation approved as maintenance treatment for women with recurrent ovarian cancer regardless of BRCA-mutation status LYNPARZA tablets also indicated in BRCA-mutated ovarian cancer beyo...

Other Sources for this Article

AstraZeneca
Michele Meixell, +1 302-885-2677
Alexandra Engel, +1 302-885-2677

NEXT ARTICLE

More From BioPortfolio on "LYNPARZA® (olaparib) Receives Additional FDA Approval in the US for Ovarian Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...